Warning letter
Rasi Laboratories, Inc. [ARCHIVED]: warning letter of Feb 17, 2011
FDA warning letter 141230 · New Jersey District Office
Key facts
| Reference number | 141230 |
|---|---|
| Company | Rasi Laboratories, Inc. [ARCHIVED] |
| Subject | CGMP/Dietary Supplement/Adulterated |
| Issue date | Feb 17, 2011 |
| Posted date | Feb 17, 2011 |
| Issuing office | New Jersey District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111, 111.70, 111.73, 111.20(d)(1)(iv), 111.25(b), 111.25(c), 111.70(a), 111.70(c)(2), 111.105(a), 111.123(a)(1), 111.123(a)(2), 111.123(a)(8) and 4 more |
| Inspection city | Cranbury |
| Inspection ZIP | 08512 |
| Inspection start date | Aug 17, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: